

## Miss Suyanee Thongchot

Department of Immunology, and Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok-Noi, Bangkok, 10700, Thailand



---

### PERSONAL INFORMATION

---

**Date of Birth:** May 27<sup>th</sup>, 1988  
**Age:** 37 years old  
**Civil status:** Single  
**Nationality:** Thai  
**Religion:** Buddhism  
**Address:** Life pinklao condo, Charan Sanitwong Road, Khwaeng Bang Yi Khan, Khet Bang Phlat, Bangkok, 10700, Thailand  
**Phone:** (+66) 90-267-7441  
**E-mail:** suyanee.thongchot@gmail.com, suyanee.tho@mahidol.ac.th

---

### EDUCATION

---

2018	Ph.D. (Medical Biochemistry and Molecular Biology)	Khon Kaen University	Thailand
2014	M.Sc. (Medical Biochemistry and Molecular Biology)	Khon Kaen University	Thailand
2011	B.Sc. (Science in Medical Technology)	Khon Kaen University	Thailand

---

### WORK EXPERIENCE

---

**2024-now** Lecturer at Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

**2019-2024** Postdoctoral researcher in Cancer Immunotherapy at Department of Immunology, and Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand  
Under supervision of Professor Chanitra Thuwajit

**2018-2019** Postdoctoral researcher in Medical Biochemistry and Molecular biology at Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand  
Under supervision of Associate Professor Nisana Namwat

**2016-2017** Research experience abroad at Medical Sciences and Biotechnology, Università del Piemonte Orientale, Department of Health Sciences, Laboratory of Molecular Pathology, Novara, Italy  
Under supervision of Professor Ciro Isidoro

---

## REFERENCES

---

Professor Chanitra Thuwajit	Deputy Head of Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Phone: (+66) 81-6437-660 E-mail: cthuwait@yahoo.com, chanitra.thu@mahidol.ac.th
Associate Professor Nisana Namwat	Head of Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand Phone: (+66) 63-635-2491 E-mail: nisana@kku.ac.th
Professor Ciro Isidoro	Head of Laboratory of Molecular Pathology and Nanobioimaging Department of Health Sciences, A. Avogadro University of Novara, Italy Phone: (+39) 0321660507/641 E-mail: ciro.isidoro@med.uniupo.it

---

## SKILLS AND INTERESTES

---

<b>Objective:</b>	To obtain a challenging career in molecular immunology of cancer research and education field in an organization that can growth and advancement in the career
<b>Personal strengths:</b>	Hard working, highly motivated, teamwork spirt, love challenging and adventure
<b>Specializations:</b>	<ul style="list-style-type: none"><li>• Autophagy in cancers (molecular, pathology and cell biology of cancers)</li><li>• Tumor microenvironment and Cancer associated fibroblasts</li><li>• Cancer immunotherapy: generation of tumor antigen specific T cells with SmartDCs and peptide pulsed DCs and PBMCs platforms</li></ul>
<b>Laboratory skills:</b>	<b><i>In vitro</i> study:</b> 2-D and 3-D cell culture systems (spheroids, tissue-derive spheroids/organoids, confocal microscope (VDO clips and photos)), protein assay, SDS- PAGE, western blotting, protein and nucleic acids extraction and analysis, PCR, real-time PCR, transient and stable transfection, RNA interference, immunofluorescence, immunohistochemistry, immunocytochemistry staining, cytofluorometry (flow cytometry), cell viability assay (SRB, MTT, MTS, colony formation, etc), invasion assay, migration assays (wound-healing scratch assay, transwell migration assay), PBMCs isolation, CAR T cells and dendritic cells culture (intracellular cytokine measurement, ELISpot and ELISA assay); <b><i>In vivo</i> study:</b> chemotherapeutic drug testing in hamster and nude mice models; <b>Computer skills:</b> Microsoft Office, Quantity One, Image J, GraphPad Prism, IBM SPSS statistics, ZEN Lite Software, QuPath and Photoshop
<b>Memberships:</b>	The Medical Technology Council (Number: 11517) The International Conference of the Genetics Society of Thailand (Number: 651004) The Allergy, Asthma, and Immunology Association of Thailand (Number: 1014)

**Languages:** Thai and English: MU grad test, TOEFL itp  
**Sports:** Volleyball and badminton  
**Hobbies:** Reading, photographing and traveling

---

## AWARDS

---

- 2026 **Travel Award: Oral and Poster presentation** on the topic “Generation of dual bispecific protein engagers targeting mesothelin and NECTIN2 for activation of cytotoxic T-lymphocytes against colorectal cancer cells” in The World Immunotherapy Council Asia-Pacific (WIC-APAC) 2026, Chang Yung-Fa Foundation International Convention Center, Taipei, Taiwan, March 28<sup>th</sup>-29<sup>th</sup>, 2026
- 2025 **The 1<sup>st</sup> Place Winner: Outstanding Oral presentation Award** on the topic “Generation of dual bispecific protein engagers targeting mesothelin and NECTIN2 for activation of cytotoxic T-lymphocytes against colorectal cancer cells” in The 19<sup>th</sup> International Symposium of the Protein Society of Thailand (PST2025), Khon Kaen, Thailand, July 7<sup>th</sup>-9<sup>th</sup>, 2025
- 2024 **Awarded the JCMT Travel grant** from The 5<sup>th</sup> edition of the International Workshop NO-CANCER 2024 "from cancer cell biology to personalized therapy" Novara, Italy, May 27<sup>th</sup>-28<sup>th</sup>, 2024
- 2023 **L'Oréal Thailand's For Women in Science 2023**, Grand Hyatt Erawan Bangkok, Thailand, November 14<sup>th</sup>, 2023
- 2023 **One of 3 “Travel Grant”** selected to participate IUIS/AAI Summer Introductory Course in Immunology at UCLA Meyer and Renee Luskin Conference Center, Los Angeles, California, USA, July 11<sup>st</sup>-16<sup>th</sup>, 2023
- 2023 **One of 4 “Thai young researcher”** selected to participate “The 14<sup>th</sup> HOPE Meeting” at Tsukuba International Congress Center (Tsukuba, Ibaraki, Japan), February 27<sup>th</sup>-March 3<sup>rd</sup>, 2023
- 2022 **The 1<sup>st</sup> Place Winner: Outstanding Oral presentation Award** on the topic “The induction of nucleolin-specific T cells against triple negative breast cancer by immunogenic nucleolin short peptides” on The 17<sup>th</sup> International Symposium of the Protein Society of Thailand (PST2022), Chiang Mai, Thailand, November 8<sup>th</sup>-11<sup>th</sup>, 2022
- 2022 **Special Awards of Young Presenters for Best Oral Presentation** on the topic “The molecular mechanisms driving tumor budding in colorectal cancer through autophagy pathway” on The 6<sup>th</sup> Cancer World Congress 2022 in “Personalized Cancer Diagnosis and Therapy” at Hotel Acores Lisbon, Lisbon, Portugal, September 28<sup>th</sup>-30<sup>th</sup>, 2022
- 2022 **Siriraj Research Excellence Award (Career Research Award for young researchers) 2022** on the topic “Cancer-associated fibroblast-derived IL-6 determines unfavorable prognosis in cholangiocarcinoma by affecting autophagy-associated chemoresponse” by Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, September 3<sup>rd</sup>-5<sup>th</sup>, 2022
- 2022 **The 1<sup>st</sup> Place Winner: Best 1<sup>st</sup> Oral Presentation Award 2022** for presentation on the topic “The production of effective nucleolin-specific T cells for the treatment of triple negative breast cancer” by on The siCMPH Siriraj International Conference in Medicine and Public Health 2022 (SICMPH2022), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, September 3<sup>rd</sup>-5<sup>th</sup>, 2022

- 2022 **The 1<sup>st</sup> Place Winner: Best 1<sup>st</sup> Oral Presentation Award 2022** for presentation on the topic “Nucleolin-specific T cell in combination with an anti-PD-L1 peptide or an autophagic stimulator: a new combinatorial therapeutic approach against triple-negative breast cancer cells” in the 38<sup>th</sup> Annual Hybrid Meeting of The Allergy, Asthma & Immunology Association of Thailand, Bangkok, Thailand, March 30<sup>th</sup>-April 1<sup>st</sup>,2022
- 2021 **Khon Kaen University Distinguished Thesis Award, Doctoral degree level in Health Sciences 2020** on the title “Activation of autophagy signaling pathways: key regulators of tumor progression and chemosensitivity in cholangiocarcinoma” Khon Kaen University, Khon Kaen, Thailand, May 17<sup>th</sup>, 2021
- 2021 **Best Poster Presentation Award 2021** for presentation on the topic “Nucleolin-specific T cell in combination with anti-PD-L1 peptide or autophagic stimulator effectively destroy triple negative breast cancer cells” in the 2<sup>nd</sup> AACR-KCA joint Conference on Precision Medicine in Solid Tumors, Seoul, Korea, November 10<sup>th</sup>-11<sup>st</sup>, 2021
- 2018 **Outstanding Best Poster Presentation Award 2018** for presentation on the topic “Autophagy in cholangiocarcinoma” in RGJ 19<sup>th</sup> congress”, Pattaya, Thailand, June 7<sup>th</sup>-9<sup>th</sup>, 2018
- 2018 **Outstanding Best Poster Presentation Award 2018** for presentation on the topic “Cancer-associated fibroblasts inhibit autophagy and promote invasiveness of cholangiocarcinoma cells through the release of IL-6-inhibited by resveratrol” by resveratrol” Cholangiocarcinoma Screening and Care Program (CASCAP), Khon Kaen University, Khon Kaen, Thailand, November 30<sup>th</sup>, 2018
- 2016 **Silver Award for Outstanding Poster Presentation 2016** for presentation on the topic “Dihydroartemisinin induces BECLIN-1-mediated autophagy-dependent cell death in cholangiocarcinoma cells” in the International Conference “Basic to Translational Medicine 2016: focus on Cancer”, Novara, Italy, October 7<sup>th</sup>, 2016
- 2016 **Gold Award for Young Investigator in Cancer Research 2016** in the International Conference “Basic to Translational Medicine 2016: focus on Cancer”, Novara, Italy, October 7<sup>th</sup>, 2016
- 2015 **Outstanding Best Poster Presentation Award 2015** for presentation on the topic “The roles of autophagy in cholangiocarcinoma progression” in the International Congress of Liver Flukes and Cholangiocarcinoma: Towards Control and Elimination, Khon Kaen, Thailand, May 12<sup>nd</sup>, 2015

---

## PUBLICATIONS

---

H-index: 19; Documents: 39; Citations: 678 (updated: August, 2025)

### International papers

1. Thongkleang T#, **Thongchot S#**, Rodponthukwaji K, Luangwattananun P, Tadpetch K, Yenichitsomanus PT, Thuwajit P, Punnakitikashem P, Thuwajit C\*. Dual Targeting of FAP-Directed Nanoparticles and FR $\alpha$ -Specific CAR-T Cells Induces Additive Anti-Tumor Effects in Triple-Negative Breast Cancer. Int J Biol Sci. 2026 Feb 18;22(5):2736-2753 (Q1, IF 10.0) #co-first author
2. Rodponthukwaji K, **Thongchot S**, Deureh S, Thongkleang T, Thaweesuvannasak M, Srichan K, Srisawat C, Thuwajit P, Nguyen KT, Tadpetch K, Thuwajit C, Punnakitikashem P\*. Development of

- cancer-associated fibroblasts-targeting polymeric nanoparticles loaded with 8-O-methylfusarubin for breast cancer treatment. *Int J Pharm X*. 2024 Oct 17;8:100294 (Q1, IF 5.2)
3. Thinyakul C, Sakamoto Y, Shimoda M, Liu Y, **Thongchot S**, Reda O, Nita A, Sakamula R, Sampattavanich S, Maeda A, Chunthaboon P, Nduru D, Niimura M, Kanamori Y, Thuwajit P, Nakayama KI, Guan KL, Satou Y, Thuwajit C, Moroishi T\*. Hippo pathway in cancer cells induces NCAM1+ $\alpha$ SMA+ fibroblasts to modulate tumor microenvironment. *Commun Biol*. 2024 Oct 17;7(1):1343 (Q1, IF 5.2)
  4. **Thongchot S**, Aksonnam K, Prasopsiri J, Warnnissorn M, Sa-Nguanraksa D, O-Charoenrat P, Thuwajit P, Yenchitsomanus PT, Thuwajit C. Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells. *BMC Med*. 2024 Sep 18;22(1):400. (Q1, IF 7.0)
  5. Jirapongwattana N#, **Thongchot S#**, Pongpaibul A, Trakarnsanga A, Quinn J, Thuwajit P, Thuwajit C, Edwards J\*. The combined tumour-based Fascin/Snail and stromal periostin reveals the effective prognosis prediction in colorectal cancer patients. *PLoS One*. 2024 Jun 27;19(6):e0304666 (Q1, IF 3.752), #co-first author
  6. **Thongchot S**, Ferraresi A, Vidoni C, Salwa A, Vallino L, Kittirat Y, Loilome W, Namwat N\*, Isidoro C\*. Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis. *Cancer Lett*. 2024 Feb 1;582:216589 (Q1, IF 9.1)
  7. Ferraresi A, **Thongchot S**, Isidoro C\*. Resveratrol Promotes Self-digestion to Put Cancer to Sleep. *J Cancer Prev*. 2024 Mar 30;29(1):1-5.
  8. Sueangoen N, Grove H, Chuangchot N, Prasopsiri J, Sanachai K, Nitchakan D, **Thongchot S**, Suriyaphol P, Sa-Nguanraksa D, Thuwajit P, Yenchitsomanus PT, Thuwajit C\*. Rungrotmongkol T, Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells, *Cancer Immunol, Immunother* 2024 Feb 13;73(3):43 (Q1, IF 6.968)
  9. Ferraresi A, **Thongchot S**, Isidoro C\*. Resveratrol promotes self-digestion to put cancer to sleep, *J Cancer Prev*. **Accepted 2024 Jan 15**
  10. **Thongchot S**, Ferraresi A, Vidoni C, Salwa A, Vallino L, Kittirat Y, Loilome W, Namwat N\*, Isidoro C\*. Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis, *Cancer Lett*. 2023 Dec 12;582:216589 (Q1, IF 9.756)
  11. **Thongchot S**, Aksonnam K, Thuwajit P, Yenchitsomanus P, Thuwajit C\*. Nucleolin-based targeting strategies in cancer treatment: Focus on cancer immunotherapy, *Int J Mol Med*, 2023 Sep;52(3):81 (Q1, IF 5.314)
  12. Chuangchot N, Jamjuntra P, Yangngam S, Luangwattananun P, **Thongchot S**, Junking M, Thuwajit P, Yenchitsomanus PT, Thuwajit C\*. Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways, *Breast Cancer Res*. 2023 Jul 21;25(1):86 (Q1, IF 8.408)
  13. **Thongchot S**, Duangkaew S, Yotchai W, Maungsomboon S, Phimolsarnti R, Asavamongkolkul A,

- Thuwajit P, Thuwajit C, Chandhanayingyong C\*. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis. *Hum Cell* 2023 Jan;36(1):456-467 (Q2, IF 4.374)
14. Kittirat Y, Suksawat M, **Thongchot S**, Padthaisong S, Phetcharaburanin J, Wangwiwatsin A, Klanrit P, Sangkhamanon S, Titapun A, Loilome W, Saya H, Namwat N\*. Interleukin-6-derived cancer-associated fibroblasts activate STAT3 pathway contributing to gemcitabine resistance in cholangiocarcinoma. *Front Pharmacol* 2022 Aug 26;13:897368 (Q1, IF 5.988)
  15. Jirapongwattana N, **Thongchot S**, Yenchitsomanus P, Warnnissorn M, O-Charoenrat P, Thuwajit P, Thuwajit C\*. Functional enhancement of self-differentiated dendritic cells for effector cells activation against mesothelin-expressing triple negative breast cancer using Toll-like receptor 4 ligand. *Oncol Rep* 2022 Jul;48(1):127 (Q1, IF 3.906)
  16. Amornsupuk K<sup>#</sup>, **Thongchot S**<sup>#</sup>, Thinyakul C, Eccles SA, Box C, Hedayat S, Thuwajit P, Thuwajit C\*. HMGB1-RAGE mediates breast cancer migration and increases PD-L1 through AKT-dependent signaling pathway. *BMC Cancer* 2022 May;24:22(1):578 (Q2, IF 3.150), <sup>#</sup>co-first author
  17. Yangngam S, Prasopsiri J, Hatthakarnkul P, **Thongchot S**, Thuwajit P, Yenchitsomanus P, Edwards J, Thuwajit C\*. Cellular localization of nucleolin can determine prognosis in cancers: a systematic and meta-analytic review. *J Mol Med* 2022 Aug;100(8):1145-1157. (Q1, IF 4.599)
  18. **Thongchot S**, Jirapongwattana N, Luangwattananun P, Chiraphappaiboon W, Chuangchot N, Soongsaja D, O-Charoenrat P, Thuwajit P, Yenchitsomanus P, Thuwajit C\*. Adoptive transfer of anti-nucleolin T cells combined with PD-L1 inhibition against triple-negative breast cancer. *Mol Cancer Ther* 2022, Mar;21:molcanther.0823.2021 (Q1, IF 6.261, Top 10% in Oncology)
  19. **Thongchot S**, Jamjuntra P, Prasopsiri J, Thuwajit P, Sawasdee N, Rungroj N, Pongvarin N, Warnnissorn M, Soongsaja D, O-Charoenrat P, Yenchitsomanus P, Thuwajit C\*. Establishment and characterization of novel highly aggressive HER2-positive and triple negative breast cancer cell lines. *Oncol Rep* 2021, Dec;46(6):254 (Q1, IF 3.906)
  20. Kittirat Y, Phetcharaburanin J, Promraksa B, Kulthawatsiri T, Wangwiwatsin A, Klanrit P, Sangkhamanon S, Jarearnrat A, **Thongchot S**, Mahalapbutr P, Loilome W, Saya H, Namwat N\* Lipidomic analyses uncover apoptotic and inhibitory effects of pyruvium pamoate on cholangiocarcinoma cells via mitochondrial membrane potential dysfunction. *Front Public Health* 2021, Dec;7:9:766455 (Q1, IF 3.018)
  21. Ferraresi A, Esposito A, Girone C, Vallino L, Salwa A, Ghezzi I, **Thongchot S**, Vidoni C, Dhanasekaran DN, Isidoro C\*. Resveratrol contrasts LPA-Induced ovarian cancer cell migration and platinum resistance by rescuing hedgehog-mediated autophagy. *Cells* 2021, Nov;17;10(11):3213 (Q1, IF 6.600)
  22. Yangngam Y, **Thongchot S**, Pongpaibul A, Vaeteewoottacharn K, Pinlaor S, Thuwajit P, Okada S, Hermoso MA, Thuwajit C\*. Intracellular IL-33 attenuates extracellular IL-33-induced cholangiocarcinoma cell proliferation and Invasion via NF- $\kappa$ B and GSK-3 $\beta$  pathways. *Anticancer Res* 2021, Oct;41(10):4917-4928 (Q2, IF 2.480)

23. **Thongchot S**, Jamjuntra P, Therasakvichya S, Warnnissorn M, Ferraresi A, Thuwajit P, Isidoro C\*, Thuwajit C\*. Interleukin-8 released by cancer-associated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells. *Int J Oncol* 2021, May;58(5):14 (Q2, IF 5.650)
24. **Thongchot S**, Vidoni C, Ferraresi A, Loilome W, Khuntikeo N, Sangkhamanon S, Titapun A, Isidoro C\*, Namwat N\*. Cancer-associated fibroblast-derived IL-6 determines unfavorable prognosis in cholangiocarcinoma by affecting autophagy-associated chemoresponse. *Cancers (Basel)* 2021, Apr;28;13(9):2134 (Q1, IF 6.639)
25. Kyaw Oo K, Kamolhan T, Soni A, **Thongchot S**, Mitrpant C, O-charoenrat P, Thuwajit C, Thuwajit P\*. Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer cells. *BMC Cancer* 2021, Jan;14;21(1):65 (Q2, IF 3.150)
26. **Thongchot S**, Singsuksawat E, Sumransub N, Pongpaibul A, Trakarnsanga A, Thuwajit P, Thuwajit C\*. Periostin regulates autophagy through integrin  $\alpha 5\beta 1$  or  $\alpha 6\beta 4$  and an AKT-dependent pathway in colorectal cancer migration. *J Cell Mol Med* 2020, Nov;24(21):12421-12432 (Q1, IF 4.486)
27. Yangngam Y, **Thongchot S**, Pongpaibul A, Vaeteewoottacharn K, Thuwajit P, Thuwajit C\*. High level of interleukin-33 in cancer cells and cancer-associated fibroblasts correlates with good prognosis and suppressed migration in cholangiocarcinoma. *J Cancer* 2020, Sep;23;11(22):6571-6581 (Q2, IF 3.565)
28. Sonongbua J, Sirtungyong S, **Thongchot S**, Kamolhan T, Utispan K, Thuwajit P, Pongpaiboon A, Wongkham S, and Thuwajit C\*. Periostin induces epithelial-to-mesenchymal transition via the integrin  $\alpha 5\beta 1$ /TWIST-2 axis in cholangiocarcinoma. *Oncol Rep* 2020, Apr;43(4):1147-1158 (Q1, IF 3.411)
29. Sumransub N, Jirapongwattana N, Jamjuntra P, **Thongchot S**, Chieochansin T, Yenchitsomanus P, Thuwajit P, Warnnissorn M, O-Charoenrat P, Thuwajit C\*. Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by T cells. *Oncol Lett* 2020, Mar;19(3):2422-2430 (Q3, IF 2.311)
30. Payoungkiattikun W, Joompang A, **Thongchot S**, Nowichai B, Jangpromma N, Klaynongsruang S\*. Evidence of multi-functional peptide activity: potential role of KT2 and RT2 for anti-inflammatory, anti-oxidative stress, and anti-apoptosis properties. *Appl Biol Chem* 2020, 63:5, doi.org/10.1186/s13765-019-0488-3 (Q2, IF 1.559)
31. **Thongchot S**, Thane M, Loilome W, Techasen A, Boonmars T, Sa-Ngiamwibool P, Titapun A, Yongvanit P, Isidoro C\*, Namwat N\*. Curative effect of xanthohumol supplementation during liver fluke-associated cholangiocarcinogenesis: potential involvement of autophagy. *J Tradit Complement Med* 2019, Feb;10;10(3):230-235 (Q1, IF 3.500)
32. **Thongchot S**, Ferraresi A, Vidoni C, Loilome W, Yongvanit P, Namwat N, Isidoro C\*. Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BECLIN1 pathway. *Mol Carcinog* 2018, Dec;57(12):1735-1750 (Q1, IF 3.851)
33. **Thongchot S**, Ferraresi A, Vidoni C, Loilome W, Yongvanit P, Namwat N, Isidoro C\*. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells. *Cancer Lett* 2018, Aug;28;430:160-171 (Q1, IF 6.491, Top 15% in Oncology)
34. Silakit R, Kitirat Y, **Thongchot S**, Loilome W, Techasen A, Ungarreevittaya P, Khuntikeo N, Yongvanit

- P, Yang JH, Kim NH, Yook JI, Namwat N\*. Potential role of HIF-1-responsive microRNA210/HIF-3 axis on gemcitabine resistance in cholangiocarcinoma cells. *PLoS One* 2018, Jun;28;13(6):e0199827 (Q1, IF 3.540, Top 10% in Multidisciplinary)
35. Kittirat Y, Techasen A, **Thongchot S**, Loilome W, Thanan R, Yongvanit P, Sungkhamanon S, Titapun A, Khuntikeo N, Namwat N\*. Suppression of 14-3-3 $\zeta$  in cholangiocarcinoma cells inhibits proliferation through attenuated Akt activity, enhancing chemosensitivity to gemcitabine. *Oncol Lett* 2018, Jan;15(1):347-353 (Q3, IF 1.554)
  36. Phanthaphol N, Techasen A, Loilome W, **Thongchot S**, Thanan R, Sungkhamanon S, Khuntikeo N, Yongvanit P, Namwat N\*. Upregulation of TCTP is associated with cholangiocarcinoma progression and metastasis. *Oncol Lett* 2017, Nov;14(5):5973-5979 (Q3, IF 1.554)
  37. Silakit R, Loilome W, Yongvanit P, **Thongchot S**, Sithithaworn P, Boonmars T, Koonmee S, Titapun A, Khuntikeo N, Chamadol N, Techasen A, Namwat N\*. Urinary microRNA-192 and microRNA-21 as potential indicators for liver fluke-associated cholangiocarcinoma risk group. *Parasitol Int* 2017, Aug;66(4):479-485 (Q1, IF 3.872)
  38. Dai X, **Thongchot S**, Dokduang H, Loilome W, Khuntikeo N, Titapun A, Ungarreevittaya P, Yongvanit P, Techasen A, Namwat N\*. Potential of Selenium Compounds as New Anticancer Agents for Cholangiocarcinoma. *Anticancer Res* 2016, Nov;36(11):5981-5988 (Q2, IF 1.937)
  39. **Thongchot S**, Loilome W, Yongvanit P, Dokduang H, Thanan R, Techasen A, Namwat N\*. Chloroquine exerts anti-metastatic activities under hypoxic conditions in cholangiocarcinoma cells. *Asian Pac J Cancer Prev* 2015;16(5):2031-5 (Q2, IF 2.390)
  40. **Thongchot S**, Yongvanit P, Loilome W, Seubwai W, Phunicom K, Tassaneeyakul W, Pairojkul C, Promkottra W, Techasen A, Namwat N\*. High expression of HIF-1 $\alpha$ , BNIP3 and PI3KC3: hypoxia-induced autophagy predicts cholangiocarcinoma survival and metastasis. *Asian Pac J Cancer Prev* 2014;15(14):5873-8 (Q2, IF 2.390)

#### National papers

1. **Thongchot S**, Penkhae U, Jamjantra P, Heepchantree W, Vaeteewoottacharn K, Thuwajit P, Thuwajit C\*. Interleukin-6 and hepatocyte growth factor produce from chromosomal aberrant cholangiocarcinoma-associated fibroblasts. *Genomics Genetics* 2020, 13(2), 33-43 (TCI Class II)
2. Jirapongwattana N, **Thongchot S**, Thuwajit C\*. The overexpressed antigens in triple negative breast cancer and the application in immunotherapy. *Genomics Genetics* 2020, 13(1),19-32 (TCI Class II)
3. Piyawajanusorn C, **Thongchot S**, Kittirat Y, Loilome W, Titapun A, Namwat N\*. Cellular senescence protein p16INK4a of cancer-associated fibroblasts (CAFs) as a prognostic indicator for cholangiocarcinoma patients. *Srinagarind Med J* 2018;33 (TCI Class II)
4. Dai X, **Thongchot S**, Loilome W, Techasen A, Yongvanit P, Namwat N\*. Expression patterns of Selenoprotein P in human cholangiocarcinoma. *Srinagarind Med J* 2014;29 (TCI Class II)
5. Kittirat Y, **Thongchot S**, Loilome W, Techasen A, Yongvanit P, Namwat N\*. Expression of 14- 3-3 sigma

protein in cholangiocarcinoma progression. *Srinagarind Med J* 2014;29 (TCI Class II)

#### Manuscript in submission process

1. **Thongchot S**, Jirapongwattana N, Prasopsiri J, Chiraphapphaiboon W, Luangwattananun P, Rungrotmongkol T, Sanachai K, Darai N, Soongsaja D, O-Charoenrat P, Thuwajit P, Yenchitsomanus P, Thuwajit C,\*. HLA class I-specific nucleolin peptides elicit antitumor immune responses against triple-negative breast cancer. Plan to submit to *Int J Biol Macromol* (Q1, IF8.2)

#### Manuscript in preparation

1. Thongkleang T#, **Thongchot S#**, Rodponthukwaji K, Luangwattananyn P, Tadpetch K, Yenchitsomanus P, Thuwajit P, Punnakitikashem P, and Thuwajit C\*. Combined Folate Receptor Alpha-CAR T Cells and Fibroblast Targeting Nanoparticles Effectively Kill Breast Cancer Cell-Fibroblast Heterospheroids. Plan to submit to *Int J Molecular Medicine* (Q1, IF 5.7)
2. **Thongchot S**, Hatthakarnkul P, Thuwajit P, Pongpaibul A, Trakarnsanga A, Angkathunyakul N, Edwards J, Thuwajit C\*. Understanding molecular mechanisms driving tumor budding in colorectal cancer through autophagy pathway. Plan to submit to *Modern Pathol* (Q1, IF8.209)
3. **Thongchot S**, Jirapongwattana N, Grove H, Sa-nguanraksa D, O-Charoenrat P, Warnnissorn M, Thuwajit P, Yenchitsomanus P, Thuwajit\*. Autologous neoantigen-specific T cells from neoantigen peptides-pulsed peripheral blood mononuclear cells for treatment of patients-derived breast cancer organoids. Plan to submit to *Sci Transl Med* (Q1, IF19.343)
4. **Thongchot S**, Sujitjooon J, Yuti P, Khanaruksombat S, Sa-nguanraksa D, O-Charoenrat P, Warnnissorn M, Thuwajit P, Yenchitsomanus P, Thuwajit\*. The pooled FRa- and Trop2-targeted CAR-T cells enhance killing against FRa/ Trop2/NECTIN2-overexpressing breast cancer cells by secreting anti-NECTIN2 ScFv. Plan to submit to *J Exp Med* (Q1, IF12.6)

---

#### **PATENT/PETTY PATENT**

---

1. **Petty patent No. อว.78.0716 (0569)** on the topic “รีคอมบิแนนต์ดีเอ็นเอที่กำหนดการสร้างที่เซลล์ที่มีตัวรับแอนติเจนแบบลูกผสมที่มีความจำเพาะต่อโปรตีนมีโซทีลินและความสามารถในการหลั่งแอนติบอดีสายเดี่ยวของพีดีแอลวัน และกรรมวิธีในการผลิตที่เซลล์ดังกล่าวสำหรับการรักษาโรคมะเร็ง” (ST 25% contribution) 5 สิงหาคม 2568
2. **Petty patent No. อว.78.0716 (0544)** on the topic “กรรมวิธีผลิตดีเอ็นเอรีคอมบิแนนต์เพื่อสร้างโปรตีนจำเพาะสองทางที่จับกับโปรตีนมีโซทีลินและซีดีสาม และโปรตีนเนกตินทูและซีดีสี่สิบแปดสำหรับการรักษาโรคมะเร็ง” (ST 50% contribution) 29 กรกฎาคม 2568
3. **Petty patent No. 2401007879** on the topic “Development of nanoparticle loaded with 8-O-methylfusarubin and conjugated with anti-fibroblast activation protein for breast cancer treatment” Primana Punnakitikashem, Thuwajit, C, Thuwajit P, **Thongchot S**, kamonlatth Rodponthukwaji, Kwanruthai Tadpetch. (ST 10% contribution) November 28<sup>th</sup>, 2024
4. **Patent No. 2401007814** on the topic “The generation of nucleolin-specific T cells from short peptides with HLA:A\*02:17 and HLA:B15:01” **Thongchot S**, Thuwajit, C, Thuwajit P, Yenchitsomanus P. (ST 50% contribution) November 26<sup>th</sup>, 2024

5. **Patent Siriraj No. 78.0716/0089** (on process) on the topic “(Production protocol of 3-dimensional breast cancer patient-derived organoids for testing cancer killing function of personalized neoantigen-specific T cells)” **Thongchot S**, Thuwajit, C, Thuwajit P, Yenchitsomanus P, Jamjuntra P. (ST 40% contribution) January 29<sup>th</sup>, 2024
6. **Petty patent No. 2303003423** on the topic “The generation of mesothelin- and nucleolin-specific T cells by combined short peptides” Aksonnam K, **Thongchot S**, Thuwajit P, Yenchitsomanus P, Thuwajit C. (ST 35% contribution) July 14<sup>th</sup>, 2023
7. **Petty patent No. 2103001236** on the topic “Smart-dendritic cells for enhancing T cell recognizing nucleolin protein” **Thongchot S**, Jirapongwattana N, Yenchitsomanus P, Thuwajit C. (ST 50% contribution), May 5<sup>th</sup>, 2021
8. **Petty patent No. 2103001527** on the topic “Smart-dendritic cells for enhancing T cell recognizing mesothelin protein” Jirapongwattana N, **Thongchot S**, Yenchitsomanus P, Thuwajit C. (ST 10% contribution) June 2<sup>nd</sup>, 2021
9. **Petty patent No. 2203002695** on the topic “Neoantigen prediction by modified pVAC-Seq pipeline and production of dendritic cell-based neoantigen-specific T cells” Sueangoen N, Grove H, Chuangchot N, **Thongchot S**, Jirapongwattana N, Yenchitsomanus P, Thuwajit P, Thuwajit, C. (ST 10% contribution) December 29<sup>th</sup>, 2021

---

## PRESENTATIONS

---

### Lectures

1. **Lecturer in 27<sup>th</sup> International Charles Heidelberger Symposium on Cancer Research** on the topic “Advancing Colorectal Cancer Therapy with Mesothelin-Targeted CAR-T cells Secreting Anti-PD-L1 scFv in Patient-Derived Organoid Models” at Avani Khon Kaen Hotel and Convention Center, Khon Kaen, Thailand November 2-5, 2025
2. **Lecturer in The 15<sup>th</sup> National Cancer Conference (NCC15)** on the topic “The immunotherapy of triple negative breast cancer: Dendritic cells- and Peptide-based adoptive T cells”, ในการประชุมวิชาการโรคมะเร็งแห่งชาติ ครั้งที่ ๑๕ “Oncology in Agile Era: Challenge, Cure and Care”, February, 24<sup>th</sup>, 2023
3. **Lecturer in The 44<sup>th</sup> International and annual conferences of the association of medical technologists of Thailand 2021 (The 44<sup>th</sup> ACMTT 2021)** “MT professional in COVID-19 era” on the topic “Nucleolin short peptide for triple negative breast cancer immunotherapy” at PEACH room Royal Cliff Hotels Group, Pattaya, Chonburi, Thailand, June 22<sup>nd</sup>-25<sup>th</sup>, 2021
4. **Lecturer in Cancer molecular biology for clinicians** on the topic “Cancer mimic model: PDX and Organoid” December 1<sup>st</sup>, 2021, Department of Immunology, Faculty of Medicine Siriraj hospital, Mahidol University, Thailand
5. **Lecturer in Research open house for medical students** on the topic “Cancer immunotherapy” (Zoom online meeting), August 11<sup>st</sup>, 2021
6. **Lecturer in Online conference on cancer immunotherapy 2021 (OCCI2021)** on the topic

“Development of short nucleolin peptide-specific T cell therapy for triple-negative breast cancer”  
(Zoom online meeting), September 21<sup>st</sup>, 2021

### Oral Presentation

1. **Oral presentation** on the topic “Generation of dual Bispecific protein engagers targeting MESOTHELIN and NECTIN2 for activation of cytotoxic T-lymphocytes against colorectal cancer cells” in The 19th International Symposium of the Protein Society of Thailand (PST2025) to be held at the Avani Khon Kaen Hotel & Convention Centre, Khon Kaen, Thailand, July 7 - 9, 2025
2. **Oral presentation** on the topic “การผลิตทีเซลล์ประสิทธิภาพสูงที่จำเพาะต่อโปรตีนมีโซทีลินและนิวคลีโอลินด้วยเปปไทด์สายสั้นผสมเพื่อกำจัดเซลล์มะเร็งด้านมนิดทริบเปิลเนกาทีฟ” ในงานประชุมวิชาการวิทยาศาสตร์การแพทย์ ครั้งที่ 33 ประจำปีงบประมาณ พ.ศ. 2568 ระหว่างวันที่ 11-13 มิถุนายน พ.ศ. 2568 ณ ศูนย์การประชุม อิมแพ็ค ฟอรั่ม เมืองทองธานี
3. **Oral presentation** on the topic “หลักฐานทางแบบจำลองสัตว์พรีคลินิกที่แสดงการป้องกันและการรักษาโรคมะเร็งท่อน้ำดีของสารสกัดธรรมชาติเรสเวอราทรอล” ในงานประชุมวิชาการวิทยาศาสตร์การแพทย์ ครั้งที่ 33 ประจำปีงบประมาณ พ.ศ. 2568 ระหว่างวันที่ 11-13 มิถุนายน พ.ศ. 2568 ณ ศูนย์การประชุม อิมแพ็ค ฟอรั่ม เมืองทองธานี
4. **Oral presentation** on the topic “Spatial Transcriptomic Profiling Reveals  $\beta$ -Catenin-Driven Tumor Budding as a Prognostic Marker and Therapeutic Target in Colorectal Cancer” in AP-SciBio2025: Asia Pacific Spatial and Single-Cell Biology Innovation Conference, SD Avenue Hotel, Bangkok, Thailand, June 20<sup>th</sup>, 2025
5. **Oral presentation** on the topic “The fifth generation of anti-trop2 CAR T cells secreting anti-NECTIN2 immune checkpoint molecule single chain variable fragment for treatment of breast cancer” in APHIA 2025, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thailand, February 5<sup>th</sup>-7<sup>th</sup>, 2025
6. **Special Invited Speaker: Oral presentation** on the topic “Cancer immunotherapy challenges and development of CAR T cells for solid tumors” in CCA Forum 2024, CARI, Faculty of Medicine, Khon Kaen University, Thailand, July 19<sup>th</sup>, 2024
7. **Special Invited Speaker: Oral presentation** on the topic “Development of Novel CAR-T cells for breast and colorectal cancer” by Natura Products for Neuroprotection and Anti-Ageing Research Unit, Faculty of Allied Health Sciences, Chulalongkorn University, Thailand, June 11<sup>st</sup>, 2024
8. **Special Invited Speaker: Oral presentation** on the topic “The immunotherapy of breast cancer: Peptide-based adoptive T cells” in The 17<sup>th</sup> Conference of Medical Biochemistry 2024, Faculty of Medicine, Khon Kaen University, Thailand, June 7<sup>th</sup>, 2024
9. **Oral presentation** on the topic “Preclinical studies exploring the effects of Resveratrol-induced autophagy on xenograft cholangiocarcinogenesis” in No-Cancer 2024, Novara, Italy, May 27<sup>th</sup>-29<sup>th</sup>, 2024
10. **Oral presentation** on the topic “The production of anti-trophoblast cell surface antigen 2 CAR T cells secreting anti-NECTIN2 immune checkpoint molecule single chain variable fragment” in The 6<sup>th</sup> European CAR T-cell Meeting, Valencia, Spain, February 15<sup>th</sup>-17<sup>th</sup>, 2024

11. **Oral presentation** on the topic “Autologous neoantigen-specific T cells from neoantigen peptides-pulsed peripheral blood mononuclear cells for treatment of triple negative breast cancer” in Thailand Hub of Talent for Cancer Immunotherapy International Meeting, Thailand, November 16<sup>th</sup>-17<sup>th</sup>, 2023
12. **Flash Talk presentation** on the topic “The production of nucleolin-specific T cells for the treatment of triple negative breast cancer patients: from SmartDCs to short peptide-activated T cells” in the 14<sup>th</sup> HOPE Meeting with Nobel Laureates, Tsukuba, Japan, February 27<sup>th</sup>-March 3<sup>rd</sup>, 2023
13. **Oral presentation** on the topic “The induction of nucleolin-specific T cells against triple negative breast cancer by immunogenic nucleolin short peptides” on The 17th International Symposium of the Protein Society of Thailand (PST2022), Chiang Mai, Thailand, November 8<sup>th</sup>-11<sup>st</sup>, 2022
14. **Oral presentation** on the topic “The molecular mechanisms driving tumor budding in colorectal cancer through autophagy pathway” on The 6th Cancer World Congress 2022 in “Personalized Cancer Diagnosis and Therapy” at Hotel Acores Lisbon, Lisbon, Portugal, September 28<sup>th</sup>-30<sup>th</sup>, 2022
15. **Oral presentation** on the topic “The Production of Effective Nucleolin-Specific T Cells for The Treatment of Triple Negative Breast Cancer” August 3rd, 2022, on Siriraj International Conference in Medicine and Public Health 2022 (SICMPH 2022) by Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, September 3<sup>rd</sup>-5<sup>th</sup>, 2022
16. **Oral presentation** on the topic “Nucleolin-specific T cell in combination with an anti-PD-L1 peptide or an autophagic stimulator: a new combinatorial therapeutic approach against triple-negative breast cancer cells” in the 38<sup>th</sup> Annual Hybrid Meeting of The Allergy, Asthma & Immunology Association of Thailand at World ballroom, Centara Grand at Central World, Bangkok, Thailand, March 30<sup>th</sup>, 2022

#### **Poster Presentation**

1. **Poster presentation** on the topic “The fifth generation anti-TROP2 CAR-T cells secreting anti-NECTIN2 immune checkpoint molecule effectively destroy breast cancer cells, in Siriraj International Conference In Medicine And Public Health (SICMPH 2024), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, July 7<sup>th</sup>-9<sup>th</sup>, 2025
2. **ePoster and Physical poster presentation** on the topic “The production of anti-trophoblast cell surface antigen 2 CAR T cells secreting anti-NECTIN2 immune checkpoint molecule single chain variable fragment” in EBMT-EHA 6<sup>th</sup> European CAR T-cell Meeting, Valencia, Spain, February 15<sup>th</sup>-17<sup>th</sup> 2024
3. **Poster presentation** on the topic “Autologous neoantigen-specific T cells from neoantigen peptides-pulsed peripheral blood mononuclear cells for treatment of triple negative breast cancer” in Siriraj International Conference In Medicine And Public Health (SICMPH 2023), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, July 19<sup>th</sup>-23<sup>rd</sup>, 2023
4. **Poster presentation** on the topic “The production of nucleolin-specific T cells for the treatment of triple negative breast cancer patients: from SmartDCs to short peptide-activated T cells” in the 14<sup>th</sup> HOPE Meeting with Nobel Laureates, Tsukuba, Japan, February 27<sup>th</sup>-March 3<sup>rd</sup>, 2023
5. **Poster presentation** on the topic “Nucleolin-specific T cell in combination with anti-PD-L1 peptide

or autophagic stimulator effectively destroy triple negative breast cancer cells” in the 2nd AACR-KCA joint Conference on Precision Medicine in Solid Tumors, Seoul, Korea, November 11<sup>st</sup>-12<sup>nd</sup>, 2021

6. **Poster presentation** on the topic “Periostin regulates autophagy in colon cancer cell migration through integrin receptors” in Kumamoto Mahidol (Siriraj)-Khon Kaen Universities, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, December 2<sup>nd</sup>, 2019
7. **Poster presentation** on the topic “Periostin regulates autophagy in colon cancer cell migration through integrin receptors” in the 2020 EACR-AACR basic and translational research conference, Lisbon, Portugal, March 2<sup>nd</sup>-4<sup>th</sup>, 2020
8. **Poster presentation** on the topic “Cancer-associated fibroblasts inhibit autophagy and promote invasiveness of cholangiocarcinoma cells through the release of IL-6-inhibited by resveratrol” by Cholangiocarcinoma Screening and Care Program (CASCAP), Khon Kaen University, Khon Kaen, Thailand, December 1<sup>st</sup>, 2018
9. **Poster presentation** on the topic “Autophagy in cholangiocarcinoma” in RGJ 19th congress the Innovation challenges toward Thailand 4.0, Pattaya, Thailand, June 7<sup>th</sup>-9<sup>th</sup>, 2018
10. **Poster presentation** on the topic “Dihydroartemisinin induces beclin-1-mediated autophagy-dependent cell death in cholangiocarcinoma cells” in the International Conference “Basic to Translational Medicine 2016: focus on Cancer”, Novara, Italy, October 6<sup>th</sup>-7<sup>th</sup>, 2016
11. **Poster presentation** on the topic “The roles of autophagy in cholangiocarcinoma progression” in the International Congress of Liver Flukes and Cholangiocarcinoma: Towards Control and Elimination at Pullman Raja Orchid Hotel, Khon Kaen, Thailand, May 11<sup>st</sup>-12<sup>nd</sup>, 2015

---

## RESEARCH GRANTS

---

### Principle investigator

1. Research Grant, Faculty of Medicine Siriraj Hospital, Mahidol University (2025-2027) on the topic “Generation of dual bispecific protein engagers targeting Mesothelin and NECTIN2 for activation of cytotoxic T-lymphocytes against colorectal cancer cells” to ST (ST, 100% contribution as PI) งบประมาณที่ได้รับ 600,000 บาท
2. Mid-Career Research Grant (2024-2026) on the topic “Advancing the Potent Fifth Generation Anti-Mesothelin Chimeric Antigen Receptor (CAR5) T Cell Therapy: A Promising Breakthrough for Colorectal Cancer Patients” to Dr. Suyanee Thongchot (ST) (ST, 100% contribution as PI) งบประมาณที่ได้รับ 1,500,000 บาท
3. Mahidol University Grant for young researchers (2021-2023) on the topic “The combined nucleolin-specific T cells and anti-PD-L1 peptide in the treatment of triple negative breast cancer” to Dr. Suyanee Thongchot (ST) (ST, 100% contribution as PI) งบประมาณที่ได้รับ 600,000 บาท
4. Research Grant, Faculty of Medicine Siriraj Hospital, Mahidol University (2022-2024) on the topic “Understanding molecular mechanisms driving tumor budding in colorectal cancer through autophagy pathway” to ST (ST, 100% contribution as PI) งบประมาณที่ได้รับ 600,000 บาท

### Co-investigator

1. Fundamental Fund: (FF 2025) on the topic “Development of targeted nanomedicine in cancer immunotherapy for breast cancer treatment-year 1” to CT (ST, 10% contribution)
2. Fundamental Fund: (FF 2024) on the topic “Development of targeted nanomedicine in cancer immunotherapy for breast cancer treatment-year 1” to CT (ST, 10% contribution)
3. Fundamental Fund: (FF 2023) on the topic “Development of targeted nanomedicine in cancer immunotherapy for breast cancer treatment-year 1” to CT (ST, 10% contribution)
4. Faculty of Medicine Siriraj Hospital, Mahidol University (2021-2024) on the topic “Development of breast cancer therapy by adoptive T cells activated by antigen-specific dendritic cells” to CT (ST, 10% contribution)
5. Research Project Grant from National Research and Innovation Information System (NRIIS 2022-2024) on the topic “Understanding molecular mechanisms driving tumour budding and the interaction of its microenvironment in colorectal cancer” to Phimmada Hatthakarnkul (ST, 10% contribution)
6. Mid-career Research Grant (2019-2022) on the topic “The development of self-differentiated DC-vaccine of specific antigen for the treatment of advanced triple-negative breast cancer patients” to CT (ST, 5% contribution)
7. Midcareer Researcher (2022-2025) on the topic “Unravelling tumor budding and cancer-associated fibroblasts crosstalk in immunosuppression as new therapeutic targets in triple negative breast cancer” to CT (ST, 10% contribution)
8. Mahidol University Grant (2021-2022) on the topic “Development of centroblast enumeration system by deep learning for effective treatment in follicular lymphoma patients” to CT (ST, 5% contribution)
9. Research Grant, Faculty of Medicine Siriraj Hospital, Mahidol University (2020-2024) on the topic “Activation of effective dendritic cells to stimulate anti-tumor T lymphocyte against breast cancer cell and breast cancer stem cell” to CT (ST, 10% contribution)

---

### THESIS CO-ADVISOR AND STUDENT TRAINER

---

#### Ph.D. students

1. Chanida Thinyakul, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, Dual Degree Program Mahidol University and Kumamoto University (current)
2. Niphath Jirapongwattana, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (graduated)

#### Master students

1. Tanva Thongklang, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (current)
2. Krittaya Aksonnam, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (graduated)

3. Parichart Jitchawan, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (graduated)
4. Suttikiat Deureh, Department of Biochemistry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (graduated)

I certify that this information above is true,

*Suyanee Thongchot*

10-3-2026

**Suyanee Thongchot**, Ph.D. (Medical Biochemistry and Molecular Biology)

Department of Immunology, and Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT),

Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Tel: (+66)-2-418-0569, Mobile: (+66)-90-267-7441, Fax: (+66)-2-418-1636

Email: [suyanee.thongchot@gmail.com](mailto:suyanee.thongchot@gmail.com), [suyanee.tho@mahidol.ac.th](mailto:suyanee.tho@mahidol.ac.th)